Evaxion A/S Sponsored ADR EVAX 深 沪
等待开盘 02-04 09:30:00 美东时间
3.19
+0.090
+2.90%
华盛通- 最 高3.325
- 今 开3.11
- 成交量 8.45万股
- 最 低 3.11
- 昨 收 3.10
- 总市值 2660.52万
- 52周最高 12.1499
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.20
- 委 比 -96.48%
- 总股本 834.02万
- 历史最高 1252.00
- 量 比 0.79
- 振 幅 6.94%
- 历史最低 3.00
- 每 手 1
- 风险率 1.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash runway through 2027.
2025-12-20 01:43
Reported Saturday, Evaxion Announces EVX-04 Triggers Specific Immune Responses Across 16 Selected ERV Fragments And Supports Broad Tumor Coverage For Acute Myeloid Leukemia
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune responses
2025-12-08 16:49
Evaxion Advances Multi-Component Cytomegalovirus Vaccine Program, EVX-V1, With New Data Demonstrating Protective Effects Of Lead Antigens
Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these
2025-11-20 21:04
Evaxion Biotech Increases Share Capital Following Warrant Exercise
Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 4, 2025, Ev...
2025-11-19 00:27
Evaxion A/S Announces 2026 Financial Calendar
Evaxion Biotech ( ($EVAX) ) has shared an announcement. On November 12, 2025, E...
2025-11-12 21:52
Evaxion Announces New Data Exploring Immune Responses Following Treatment With AI-designed Personalized Cancer Vaccine EVX-01
Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with
2025-11-08 06:16
Evaxion Biotech Q3 EPS $0.01 Beats $(0.21) Estimate, Sales $7.492M Beat $2.500M Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.21) by 104.76 percent. This is a 125 percent increase over losses of $(0.04) per share from
2025-11-06 20:32
Evaxion Unveils AI-Designed Cancer Vaccine Candidate EVX-04
Evaxion Biotech ( ($EVAX) ) has shared an update. On November 3, 2025, Evaxion ...
2025-11-03 22:48
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
